Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• a recent approach for thrombosis has involved inhibiting thrombin enzyme activity, and compounds used for this purpose have included heparin, low molecular weight heparin, hirudin, argatroban, hirulog and the like. All such compounds inhibit the enzyme activity of thrombin, and work by inhibiting fibrin blood clot formation without specifically inhibiting the effect of thrombin on cells. Bleeding tendency is therefore a common side effect encountered in the clinic.
• the role of thrombin in thrombosis is not limited to its blood clotting activity, as it is believed to also participate in platelet aggregation at sites of vascular injury occurring as a result of the activation of platelet thrombin receptor.
• the thrombin receptor (PAR1) has recently been cloned (Vu et al., Cell, 1991, 64: 1057-1068), opening an important door to development of substances which target cellular thrombin receptors.
• Detailed examination of the amino acid sequence of this thrombin receptor has revealed a thrombin binding site and hydrolysis site located in the 100 residue amino terminal domain of the receptor. Later research by amino acid mutation in the receptor has established that limited hydrolysis of this portion of the thrombin receptor by thrombin is necessary for receptor activation (Vu et al., Nature, 1991, 353: 674-677).
• a synthetic peptide corresponding to the amino acid sequence newly generated by hydrolysis of the thrombin receptor (the synthetic peptide is known as “thrombin receptor activating peptide”, or TRAP) can activate receptors which have not been hydrolyzed by thrombin. This suggests that the cleavage of the receptor, the new amino acid sequence generated at the amino terminal (known as the “tethered ligand peptide”) functions as the ligand and interacts with the distal binding site. Further studies of TRAP have confirmed homology of the thrombin receptors present in platelet, endothelial cell, fibroblast and smooth muscle cell (Hung et al., J. Cell. Biol. 1992, 116: 827-832; and Ngaiza, Jaffe, Biochem. Biophys. Res. Commun. 1991, 179: 1656-1661).
• thrombin receptor antagonists are expected to exhibit excellent effects for therapy or prevention of diseases associated with thrombin, and therefore offer promise for effective therapy or prevention of, for example, thrombosis, vascular restenosis, deep venous thrombosis, pulmonary embolism, cerebral infarction, heart diseases, disseminated intravascular coagulation, hypertension, inflammatory diseases, rheumatism, asthma, glomerulonephritis, osteoporosis, neurological diseases, malignant tumors, and the like. It has been highly desired to provide thrombin receptor antagonists which are satisfactory in numerous aspects including pharmacological activity, thrombin receptor specificity, safety, dosage and oral efficacy.
• the present invention provides a compound represented by the formula:
• ring C represents an optionally substituted aromatic hydrocarbon ring or pyridine ring
• R 1 represents (1) hydrogen, (2) cyano, (3) halogen or (4) a group selected from Substituent Group A below
• R 201 represents (1) hydrogen or (2) a group selected from Substituent Group D below
• R 6 represents (1) hydrogen, (2) C 1-6 alkyl, (3) acyl, (4) carbamoyl, (5) hydroxyl, (6) C 1-6 alkoxy, (7) C 1-6 alkyloxycarbonyloxy, (8) C 3-8 cycloalkyl, (9) C 1-6 alkyloxycarbonyl optionally substituted with acyloxy or (10) a C 6-14 aromatic hydrocarbon ring group or a 5- to 14-membered aromatic heterocyclic group (each of the foregoing members being optionally substituted with at least one group selected from Substituent Group E below);
• Y 1 represents a single bond, —(CH 2 ) m —, —CR
• R 10 , R 11 , R 12 , R 13 and R 14 are the same or different and each independently represents (1) hydrogen, (2) cyano, (3) halogen, (4) nitro or (5) a group selected from Substituent Group B below, and R 11 and R 12 or R 12 and R 13 may bond together to form a 5- to 8-membered heterocycle optionally having 1 to 4 hetero atoms selected from N, S and O and optionally substituted with at least one group selected from Substituent Group F below] or (3) a 5- to 14-membered aromatic heterocyclic group optionally substituted with at least one group selected from Substituent Group G below.
• ⁇ Substituent Group B> represents moieties selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, acyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 3-8 cycloalkyloxy, amino, C 16 aminoalkyl, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, ureido, sulfonylamino, sulfonyl, sulfamoyl, C 3-8 cycloalkyl, a 5- to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membered aromatic heterocyclic group, each of the foregoing members being optionally substituted with at least one group selected from Substituent Group B
• ⁇ Substituent Group B′> represents moieties selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, oxo, cyano, C 1-6 cyanoacyl, C 2-7 acyl, C 1-6 alkanoyl, benzoyl, aralkanoyl, C 1-6 alkoxyalkylcarbonyl, C 1-6 hydroxyalkylcarbonyl, carboxyl, C 1-6 carboxyalkyl, C 1-6 carboxyalkyloxy, carbamoyl, carbamoylalkyloxy, C 1-6 alkoxycarbonyl, C 1-10 alkoxycarbonyl-C 1-6 alkyl, C 1-10 alkoxycarbonyl-C 1-6 alkyloxy, C 1-6 monoalkylaminocarbonyl, C 2-6 dialkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 1-10 alkoxyalkyl, C 1-10
• Substituent Group D> represents moieties selected from the group consisting of cyano, halogen, C 2-8 alkenyl, C 2-8 alkynyl, acyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 3-8 cycloalkyloxy, amino, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, ureido, ureylene, sulfonylamino, sulfonyl, sulfamoyl and C 1-6 alkyl optionally substituted with at least one group selected from Substituent Group D′ below;
• ⁇ Substituent Group D′> represents moieties selected from the group consisting of carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 3-8 cycloalkyloxy, amino, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, sulfonylamino, sulfonyl, sulfamoyl, a 5- to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membered aromatic heterocyclic group;
• ⁇ Substituent Group E> represents moieties selected from the group consisting of C 1-6 alkyl, cyano, acyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 3-8 cycloalkyloxy, amino, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, ureido, ureylene, sulfonylamino, sulfonyl, sulfamoyl, halogen and C 3-8 cycloalkyl;
• ⁇ Substituent Group F> represents moieties selected from the group consisting of (1) hydrogen, (2) cyano, (3) halogen, (4) oxo and (5) C 1-6 alkyl, alkenyl, alkynyl, acyl, C 1-6 alkanoyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 3-8 cycloalkyloxy, amino, imino, C 1-6 aminoalkyl, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, ureido, sulfonylamino, sulfonyl, sulfamoyl, C 3-8 cycloalkyl, a 5-to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membere
• ⁇ Substituent Group F′> represents moieties selected from the group consisting of C 1-6 alkyl, oxo, cyano, acyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, benzyloxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 3-8 cycloalkyloxy, amino, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, ureido, ureylene, C 1-6 alkylsulfonylamino, C 1-6 alkylsulfonyl, sulfamoyl, halogeno, C 3-8 cycloalkyl, a 5- to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membered aromatic heterocyclic group;
• ⁇ Substituent Group G> represents moieties selected from the group consisting of C 1-6 alkyl, cyano, acyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, sulfonyl, sulfamoyl, halogeno and C 3-8 cycloalkyl. ⁇ or salt thereof.
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein ring C represents a further optionally substituted benzene ring or a further optionally substituted pyridine ring; R 1 represents C 1-6 alkyl, C 2-6 alkenyl or C 1-6 alkoxy, each of the foregoing members being optionally substituted with at least one group selected from Substituent Group A′′ below:
• ⁇ Substituent Group A′′> represents moieties selected from the group consisting of C 1-6 alkyl, acyl, carboxyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 1-6 alkylamino, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membered aromatic heterocyclic group, wherein the C 6-14 aromatic hydrocarbon ring group and the 5- to 14-membered aromatic heterocyclic group may be substituted with at least one group selected from the group consisting of C 1-6 alkyl, carboxyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, nitro, C 1-6 alkylamino, acylamino, sulfonylamino and halogen;
• R 201 represents a group selected from the group consisting of hydrogen, halogen, acyl, carboxyl
• R 10 , R 11 , R 12 , R 13 and R 14 are the same or different and each independently represents a group selected from the group consisting of hydrogen, C 1-6 alkyl, hydroxyl, C 1-6 alkoxy, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, a 5- to 14-membered non-aromatic heterocyclic group and C 1-6 alkyloxycarbonyloxy, wherein R 11 and R 12 or R 12 and R 13 may bond together to form a 5- to 8-membered heterocycle (i) optionally having 1 to 4 hetero atoms selected from N, S and O and (ii) optionally substituted with at least one group selected from the group consisting of cyano, oxo, and C 1-6 alkyl, acyl, C 1-6 alkanoyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxy
• Substituent Group F′′> represents moieties selected from the group consisting of C 1-6 alkyl, oxo, cyano, acyl, carboxyl and C 1-6 alkoxy].
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Y 1 is —CH 2 —.
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Y 2 is —CO—.
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Y 1 is —CH 2 — and Y 2 is —CO—.
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Y 1 is a single bond, Y 2 is a single bond and Ar is hydrogen.
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Ar is a group represented by the formula:
• the invention provides a compound according to ⁇ 7> or salt thereof, wherein R 10 and R 14 are hydrogen.
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Ar is (1) a group represented by the formula:
• R 10 , R 11 , R 12 , R 13 and R 14 have the same definitions given above] or (2) a 5- to 14-membered aromatic heterocyclic group optionally substituted with at least one group selected from Substituent Group G above.
• the invention provides a compound according to ⁇ 9> or salt thereof, wherein R 10 and R 14 are hydrogen.
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Ar is a group represented by the formula:
• R 11 and R 13 have the same definitions given above, and R 15 represents (1) hydrogen or (2) a group selected from Substituent Group H below, and R 11 and R 15 may bond together to form a 5- to 8-membered heterocycle optionally substituted with at least one group selected from Substituent Group F above and optionally having 1 or 2 hetero atoms selected from N, S and O.
• ⁇ Substituent Group H> represents moieties selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, acyl, C 1-6 alkoxycarbonyl, aminocarbonyl, C 1-6 alkylaminocarbonyl, C 3-8 cycloalkyl, C 1-6 aminoalkyl, sulfonyl, C 3-8 cycloalkylamino, a 5- to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membered aromatic heterocyclic group, each of the foregoing members being optionally substituted with at least one group selected from Substituent Group H′ below;
• ⁇ Substituent Group H′> represents moieties selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, oxo, cyano, C 1-6 cyanoalkyl, C 2-7 acyl, C 1-6 alkanoyl, benzoyl, aralkanoyl, C 1-6 alkoxyalkylcarbonyl, C 1-6 hydroxyalkylcarbonyl, carboxyl, C 1-6 carboxyalkyl, C 1-6 carboxyalkyloxy, carbamoyl, carbamoylalkyloxy, C 1-6 alkoxycarbonyl, C 1-10 alkoxycarbonyl-C 1-6 alkyl, C 1-10 alkoxycarbonyl-C 1-6 alkyloxy, C 1-6 monoalkylaminocarbonyl, C 2-6 dialkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 1-10 alkoxyalkyl, C 1-10 alk
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Ar is a group represented by the formula:
• R 11 and R 15 have the same definitions given above, and R 16 represents (1) hydrogen or (2) a group selected from Substituent Group H above, and R 11 and R 15 or R 15 and R 16 may bond together to form a 5- to 6-membered heterocycle optionally substituted with at least one group selected from Substituent Group F above and optionally having 1 or 2 hetero atoms selected from N, S and O].
• the invention provides a compound according to ⁇ 1> or salt thereof, wherein Ar is a group represented by the formula:
• R 11 and R 15 have the same definitions given above, and R 17 and R 18 are the same or different and each independently represents (1) hydrogen or (2) a group selected from Substituent Group I below, and R 11 and R 15 , R 15 and R 17 , R 15 and R 18 or R 17 and R 18 may bond together to form a 5- to 8-membered heterocycle optionally substituted with at least one group selected from Substituent Group F above and optionally having 1 or 2 hetero atoms selected from N, S and O.
• Substituent Group I> represents moieties selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, acyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, C 16 aminoalkyl, sulfonyl, sulfamoyl, C 3-8 cycloalkyl, a 5- to 14-membered non-aromatic heterocyclic group, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membered aromatic heterocyclic group, each of the foregoing members being optionally substituted with at least one group selected from Substituent Group I′ below;
• ⁇ Substituent Group I′> represents moieties selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, oxo, cyano, C 1-6 cyanoalkyl, C 2-7 acyl, C 1-6 alkanoyl, benzoyl, aralkanoyl, C 1-6 alkoxyalkylcarbonyl, C 1-6 hydroxyalkylcarbonyl, carboxyl, C 1-6 carboxyalkyl, C 1-6 carboxyalkyloxy, carbamoyl, carbamoylalkyloxy, C 1-6 alkoxycarbonyl, C 1-10 alkoxycarbonyl-C 1-6 alkyl, C 1-10 alkoxycarbonyl-C 1-6 alkyloxy, C 1-6 monoalkylaminocarbonyl, C 2-6 dialkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 1-10 alkoxyalkyl, C 1-10 alk
• the invention provides a pharmaceutical composition comprising a compound according to ⁇ 1> or salt thereof.
• the invention provides a composition according to ⁇ 14>, wherein the composition is useful as a thrombin receptor antagonist.
• the invention provides a composition according to ⁇ 14>, wherein the composition is useful as a thrombin receptor PAR1 antagonist.
• the invention provides a composition according to ⁇ 14>, wherein the composition is useful as a platelet aggregation inhibitor.
• the invention provides a composition according to ⁇ 14>, wherein the composition is useful as a proliferation inhibitor for smooth muscle cells.
• the invention provides a composition according to ⁇ 14>, wherein the composition is useful as a proliferation inhibitor for endothelial cells, fibroblasts, nephrocytes, osteosarcoma cells, muscle cells, cancer cells and/or glia cells.
• the invention provides a composition according to ⁇ 14>, wherein the composition is useful as a therapeutic or prophylactic agent for thrombosis, vascular restenosis, deep venous thrombosis, pulmonary embolism, cerebral infarction, heart disease, disseminated intravascular coagulation, hypertension, inflammatory disease, rheumatism, asthma, glomerulonephritis, osteoporosis, neurological disease and/or malignant tumor.
• the invention provides the use of a compound according to ⁇ 1> or salt thereof for the manufacture of a thrombin receptor antagonist.
• the invention provides the use according to ⁇ 21>, wherein the thrombin receptor antagonist is a PAR1 receptor antagonist.
• the invention provides the use of a compound according to ⁇ 1> or salt thereof for the manufacture of a platelet aggregation inhibitor.
• the invention provides a therapeutic method for treating or preventing a disease associated with thrombin receptors, comprising administering to a patient suffering from the disease, a therapeutically effective dose of a compound according to ⁇ 1> or salt thereof.
• the invention provides a therapeutic method for treating or preventing a proliferative disease of endothelial cells, fibroblasts, nephrocytes, osteosarcoma cells, muscle cells, cancer cells and/or glia cells, comprising administering to a patient suffering from the disease, a therapeutically effective dose of a compound according to ⁇ 1> or salt thereof.
• the compounds of the invention and their salts may also be in the form of anhydrides or solvates such as hydrates, and all such forms are included within the scope of the claims of the present specification.
• Metabolites of the compounds of the invention produced by degradation in the body, as well as prodrugs of the compounds of the invention and their salts, are also encompassed within the scope of the claims of the present specification.
• halogen used throughout the present specification refers to an atom such as fluorine, chlorine, bromine or iodine, and preferably fluorine, chlorine or bromine.
• C 1-6 alkyl used throughout the present specification refers to an alkyl group of 1 to 6 carbons, such as, for example, linear or branched alkyl groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-ethylpropyl, n-hexyl, 1-methyl-2-ethylpropyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1-propylpropyl, 1-methylbutyl, 2-methylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl,
• C 2-6 alkenyl used throughout the present specification refers to an alkenyl group of 2 to 6 carbons, such as, for example, vinyl, allyl, 1-propenyl, 2-propenyl, isopropenyl, 2-methyl-1-propenyl, 3-methyl-1-propenyl, 2-methyl-2-propenyl, 3-methyl-2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 1-hexenyl, 1,3-hexanedienyl and 1,6-hexanedienyl.
• C 2-6 alkynyl used throughout the present specification refers to an alkynyl group of 2 to 6 carbons, such as, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 3-methyl-1-propynyl, 1-ethynyl-2-propynyl, 2-methyl-3-propynyl, 1-pentynyl, 1-hexynyl, 1,3-hexanediynyl and 1,6-hexanediynyl.
• C 3-8 cycloalkyl used throughout the present specification refers to a cycloalkyl group composed of 3 to 8 carbons, such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
• C 3-8 cycloalkenyl used throughout the present specification refers to a C 3-8 cycloalkenyl group composed of 3 to 8 carbons, such as, for example, cyclopropen-1-yl, cyclopropen-3-yl, cyclobuten-1-yl, cyclobuten-3-yl, 1,3-cyclobutadien-1-yl, cyclopenten-1-yl, cyclopenten-3-yl, cyclopenten-4-yl, 1,3-cyclopentadien-1-yl, 1,3-cyclopentadien-2-yl, 1,3-cyclopentadien-5-yl, cyclohexen-1-yl, cyclohexen-3-yl, cyclohexen-4-yl, 1,3-cyclohexadien-1-yl, 1,3-cyclohexadien-2-yl, 1,3-cyclohexadien-5-yl, 1,3-cyclohexa
• C 1-6 alkoxy refers to an alkoxy group of 1 to 6 carbons, such as, for example, methoxy, ethoxy, n-propoxy, iso-propoxy, sec-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, iso-pentyloxy, sec-pentyloxy, n-hexoxy, iso-hexoxy, 1,1-dimethylpropyloxy, 1,2-dimethylpropoxy, 2,2-dimethylpropyloxy, 2-ethylpropoxy, 1-methyl-2-ethylpropoxy, 1-ethyl-2-methylpropoxy, 1,1,2-trimethylpropoxy, 1,1,2-trimethylpropoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutyloxy, 1,3-dimethylbutyloxy, 2-eth
• C 2-6 alkenyloxy refers to an alkenyloxy group of 2 to 6 carbons, such as, for example, vinyloxy, allyloxy, 1-propenyloxy, 2-propenyloxy, isopropenyloxy, 2-methyl-1-propenyloxy, 3-methyl-1-propenyloxy, 2-methyl-2-propenyloxy, 3-methyl-2-propenyloxy, 1-butenyloxy, 2-butenyloxy, 3-butenyloxy, 1-pentenyloxy, 1-hexenyloxy, 1,3-hexanedienyloxy and 1,6-hexanedienyloxy.
• acyl used throughout the present specification refers to an atomic group derived by removing the OH group from a carboxyl group of a carboxylic acid, and it is preferably a C 2-7 acyl group (an atomic group derived by removing the OH group from a carboxyl group of a C 2-7 carboxylic acid (more preferably fatty acid)), of which examples include acetyl, propionyl, butyroyl and benzoyl.
• C 6-14 aromatic hydrocarbon ring group refers to an aromatic hydrocarbon ring group composed of 6 to 14 carbons, and includes monocyclic groups as well as fused rings such as bicyclic and tricyclic groups. Examples include phenyl, indenyl, 1-naphthyl, 2-naphthyl, azulenyl, heptalenyl, biphenyl, indacenyl, acenaphthyl, fluorenyl, phenalenyl, phenanthrenyl, anthracenyl, cyclopentacyclooctenyl and benzocyclooctenyl.
• 5- to 14-membered aromatic heterocyclic group used throughout the present specification refers to a monocyclic, bicyclic or tricyclic 5- to 14-membered aromatic heterocyclic group comprising one or more hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen.
• Examples include (i) nitrogen-containing aromatic heterocyclic groups such as pyrrolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, tetrazolyl, benzotriazolyl, pyrazolyl, imidazolyl, benzimidazolyl, indolyl, isoindolyl, indolidinyl, purinyl, indazolyl, quinolyl, isoquinolyl, quinolidyl, phthalazyl, naphthylidinyl, quinoxalyl, quinazolinyl, cinnolinyl, pteridinyl, imidazotriazinyl, pyrazinopyridazinyl, acridinyl, phenanthridinyl, carbazolyl, carbazolinyl, perimidinyl, phenanthrolinyl, phenacen
• 5- to 14-membered non-aromatic heterocyclic group refers to a monocyclic, bicyclic or tricyclic 5- to 14-membered non-aromatic heterocyclic group comprising one or more hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen.
• Examples include pyrrolidyl, pyrrolyl, piperidyl, piperazyl, imidazolyl, pyrazolidyl, imidazolidyl, morpholyl, tetrahydrofuryl, tetrahydropyranyl, aziridinyl, oxiranyl and oxathiolanyl.
• Non-aromatic heterocyclic groups also include a pyridone ring-derived group, and a non-aromatic fused ring (for example, a phthalimide ring-derived group and a succinimide ring-derived group).
• 5- to 8-membered heterocycle used throughout the present specification refers to a 5- to 8-membered aromatic or non-aromatic heterocycle.
• aryl used throughout the present specification refers to an atomic group remaining after elimination of one hydrogen atom bonded to the ring of the aromatic hydrocarbon. Examples include phenyl, tolyl, xylyl, biphenyl, naphthyl, anthoryl and phenanthoryl.
• alkylidene used throughout the present specification refers to a divalent group derived by the loss of two hydrogen atoms from the same carbon of an aliphatic hydrocarbon (preferably a C 1-6 alkane). Examples include ethylidene and the like.
• hetero atom used throughout the present specification refers specifically to oxygen, sulfur, nitrogen, phosphorus, arsenic, antimony, silicon, germanium, tin, lead, boron, mercury and the like, and preferably oxygen, sulfur and nitrogen.
• n- signifies a normal type or primary substituent
• sec- signifies a secondary substituent
• t- signifies a tertiary substituent
• i- signifies an iso type substituent
• _ring C is preferably a benzene ring or pyridine ring optionally having an additional substituent (R 201 ), with benzene being more preferred.
• R 201 The position of the substituent (R 201 ) is not particularly restricted, but it is preferably the 5- or 6-position from the nitrogen atom to which Y 1 is connected.
• R 201 is a group selected from the group consisting of hydrogen, halogen, acyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, amino, C 1-6 alkylamino, C 3-8 cycloalkylamino, sulfonylamino and sulfamoyl.
• R 1 is (i) C 1-6 alkyl, (ii) C 2-6 alkenyl or (iii) C 1-6 alkoxy, each of the foregoing members being optionally substituted with at least one group selected from Substituent Group A′′ below, with (i) being more preferred:
• ⁇ Substituent Group A′′> represents moieties selected from the group consisting of C 1-6 alkyl, acyl, carboxyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 1-6 alkylamino, a C 6-14 aromatic hydrocarbon ring group and a 5- to 14-membered aromatic heterocyclic group, wherein the C 6-14 aromatic hydrocarbon ring group and the 5- to 14-membered aromatic heterocyclic group may be substituted with at least one group selected from the group consisting of C 1-6 alkyl, carboxyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, nitro, C 1-6 alkylamino, acylamino, sulfonylamino and halogen.
• R 6 is a group selected from the group consisting of hydrogen, C 1-6 alkyl and C 1-6 alkyloxycarbonyl optionally substituted with acyloxy.
• Y 1 is a single bond or —(CH 2 ) m — [wherein m represents an integer of 1 to 3] and Y 2 is a single bond or —CO—, there being more preferred (i) the combination that Y 1 is —CH 2 — and Y 2 is —CO—, and (ii) the combination that Y 1 and Y 2 are each a single bond.
• Ar is hydrogen or a group represented by the formula:
• Ar is preferably a group represented by general formula (II) above, and (ii) when Y 1 and Y 2 are each a single bond, Ar is preferably hydrogen.
• R 10 , R 11 , R 12 , R 13 and R 14 are the same or different and are each preferably a group selected from the group consisting of hydrogen, C 1-6 alkyl, hydroxyl, C 1-6 alkoxy, C 1-6 alkylamino, C 3-8 cycloalkylamino, acylamino, a 5- to 14-membered non-aromatic heterocyclic group and C 1-6 alkyloxycarbonyloxy, and more preferably R 10 and R 14 are each hydrogen.
• R 11 and R 12 or R 12 and R 13 may bond together to form a 5- to 8-membered heterocyclic ring (i) optionally having 1 to 4 hetero atoms selected from N, S and O and (ii) optionally substituted with at least one group selected from the group consisting of cyano, oxo, and C 1-6 alkyl, acyl, C 1-6 alkanoyl, carboxyl, carbamoyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl, C 1-6 alkoxy, C 3-8 cycloalkyloxy, amino, C 1-6 alkylamino, sulfonyl and a 5- to 14-membered non-aromatic heterocyclic group (each of the foregoing members being optionally substituted with at least one group selected from Substituent Group F′′ below:
• Substituent Group F′′> represents moieties selected from the group consisting of C 1-6 alkyl, oxo, cyano, acyl, carboxyl and C 1-6 alkoxy).
• a preferred group for (ii) above is the group consisting of cyano, oxo, C 1-6 alkyl, cyano-C 1-6 alkyl, C 1-6 acyl, carboxyl, C 1-6 alkoxycarbonyl, C 1-6 alkylaminocarbonyl, hydroxyl and C 1-6 alkoxy.
• R 10 and R 14 are each hydrogen, and Ar is a group represented by the formula:
• R 15 represents (1) hydrogen or (2) a group selected from Substituent Group H above, and R 11 and R 15 may bond together to form a 5- to 8-membered heterocycle optionally substituted with at least 1 group selected from Substituent Group F above and optionally having 1 or 2 hetero atoms selected from N, S and O];
• R 11 and R 15 have the same definitions given above, R 16 represents (1) hydrogen or (2) a group selected from Substituent Group H above, and R 11 and R 15 or R 15 and R 16 may bond together to form a 5- to 6-membered heterocycle optionally substituted with at least one group selected from Substituent Group F above and optionally having 1 or 2 hetero atoms selected from N, S and O];
• R 11 and R 15 have the same definitions given above, R 17 and R 18 are the same or different and each independently represents (1) hydrogen or (2) a group selected from Substituent Group I, and R 11 and R 15 R 15 and R 17 R 15 and R 18 or R 17 and R 18 may bond together to form a 5- to 8-membered heterocycle optionally substituted with at least one group selected from Substituent Group F above and optionally having 1 or 2 hetero atoms selected from N, S and O].
• salt used throughout the present specification is not particularly restrictive so long as the salt is formed with a compound of the invention and is pharmacologically acceptable.
• examples include hydrogen halide acid salts (for example, hydrofluoride, hydrochloride, hydrobromide and hydroiodide), inorganic acid salts (for example, sulfate, nitrate, perchlorate, phosphate, carbonate and bicarbonate), organic carboxylate (for example, acetate, trifluoroacetate, oxalate, maleate, tartarate, fumarate and citrate), organosulfonate (for example, methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate and camphorsulfonate), amino acid salts (for example, aspartate and glutamate), quaternary amine salts, alkali metal salts (
• Production Process M is an exemplary synthetic method for benzimidazole derivatives.
• This scheme represents an exemplary synthetic method for a benzimidazole derivative.
• Ar has the same definition as that for the compounds represented by formula (I) in claim 1 .
• R1 represents optionally substituted alkyl, optionally substituted alkoxy or optionally substituted amino.
• R2 has the same definition as R1 in the compounds represented by formula (I) in claim 1 .
• Step 1 represents a step of alkylation, whereby compound (M1-b) is obtained based on the method described in Antonio Da Settimo et al., J. Het. Chem., 23,1833 (1986) Yasuo Kikugawa, Synthesis, 124(1981).
• Step 2 represents a step of alkylation, wherein compound (M1-c) may be obtained as a hydrobromide by dissolving a compound (M1-b) and a 2-haloethanone derivative in dimethylformamide, acetonitrile, an alcohol or the like and selecting the conditions from room temperature to reflux temperature, depending on the compound.
• a compound (M1-b) may be reacted with sodium hydride in tetrahydrofuran or dimethylformamide and then reacted with a 2-haloethanone derivative at room temperature or while cooling on ice to yield a salt-free form of compound (M1-c), prior to treatment with an acid.
• an ammonium salt may be obtained by reaction with a 5 N hydrochloric acid in an organic solvent or with 5 N hydrobromic acid in acetic acid.
• This scheme is an exemplary synthetic method for a benzimidazole derivative.
• Ar has the same definition as that for the compounds represented by formula (I) in claim 1 .
• R1 represents optionally substituted lower alkyl, lower alkoxy or lower amino.
• R2 has the same definition as R1 in the compounds represented by formula (I) in claim 1 .
• Step 1 represents a step of alkylation, wherein compound (M2-b) may be obtained by reaction with an amine in ethanol, methanol, acetonitrile or dimethylformamide at room temperature to 120° C., in the presence of sodium carbonate, potassium carbonate, cesium carbonate or potassium tert-butoxide.
• Step 2 represents a step of reduction of the nitro group. Reaction is conducted in tetrahydrofuran, ethyl acetate, methanol or ethanol under a hydrogen atmosphere, in the presence of a catalytic amount of palladium-carbon. Alternatively, compound (M2-c) may be obtained by reaction with iron in hydrated methanol or hydrated ethanol at the reflux temperature of the solvent, in the presence of ammonium chloride.
• Step 3 represents a step of imidazole ring formation, wherein compound (M2-d) may be obtained by reaction with cyanogen bromide in ethanol or methanol at room temperature to reflux temperature.
• Step 4 represents a step of alkylation, wherein compound (M2-e) may be obtained as hydrobromide by dissolving compound (M2-d) and a 2-haloethanone derivative in dimethylformamide, acetonitrile, an alcohol or the like and selecting the conditions from room temperature to reflux temperature, depending on the compound.
• compound (M2-d) may be reacted with sodium hydride in tetrahydrofuran or dimethylformamide and then reacted with a 2-haloethanone derivative at room temperature or while cooling on ice to yield a salt-free form of compound (M1-e), prior to treatment with an acid.
• an ammonium salt may be obtained by reaction with a 5 N hydrochloric acid in an organic solvent or 5 N hydrobromic acid in acetic acid.
• This scheme is an exemplary synthetic method for a benzimidazole derivative.
• Ar has the same definition as that for the compounds represented by formula (I) in claim 1 .
• R1 represents optionally substituted lower alkyl, lower alkoxy or lower amino.
• R2 has the same definition as R1 in the compounds represented by formula (I) in claim 1 .
• Step 1 represents a step of alkylation, wherein compound (M3-b) may be obtained by reaction with an amine in ethanol, methanol, acetonitrile or dimethylformamide at room temperature to 120° C., in the presence of sodium carbonate, potassium carbonate, cesium carbonate or potassium tert-butoxide.
• Step 2 represents a step of imidazole ring formation, wherein compound (M3-c) may be obtained by reaction with cyanogen bromide in ethanol or methanol at room temperature to reflux temperature.
• Step 3 represents a step of alkylation, wherein compound (M3-d) may be obtained as hydrobromide by dissolving compound (M3-c) and a 2-haloethanone derivative in dimethylformamide, acetonitrile, an alcohol or the like and selecting the conditions from room temperature to reflux temperature, depending on the compound.
• compound (M3-c) may be reacted with sodium hydride in tetrahydrofuran or dimethylformamide and then reacted with a 2-haloethanone derivative at room temperature or while cooling on ice to yield a salt-free form of compound (M3-d), prior to treatment with an acid.
• an ammonium salt may be obtained by reaction with 5 N hydrochloric acid in an organic solvent or with 5 N hydrobromic acid in acetic acid.
• R1 represents hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted alkoxy.
• R2 has the same definition as R6 and R7 in Production Process MO.
• Step 1 represents a step of Friedel-Crafts acylation.
• Compound (AP1-b) may be obtained by reacting compound (AP1-a) with acetyl chloride in a solvent such as dichloromethane or toluene, in the presence of a Lewis acid such as aluminum chloride, zinc chloride or tin (II) chloride, at ⁇ 70° C. to room temperature.
• a Lewis acid such as aluminum chloride, zinc chloride or tin (II) chloride
• Step 2 represents a step of nitration.
• Compound (AP1-c) may be obtained by reaction with fuming nitric acid or concentrated nitric acid in a solvent such as toluene, hexane, ether or acetic anhydride. Alternatively, the reaction may be conducted by generating nitric acid from sodium nitrate and hydrochloric acid.
• Step 3 represents a step of introducing a substituent R2 having any of various structures at the hydroxyl group of compound (AP1-c).
• Compound (AP1-d) may be obtained by reaction with a halide, mesylate or tosylate in a solvent such as dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane or acetone, in the presence of a base such as potassium carbonate, cesium carbonate, sodium hydrogencarbonate, trialkylamine, a pyridine derivative or sodium hydride.
• R2 has the same definition as R6 in Step 1 of Production Process MO.
• Step 4 represents a step of reduction of the nitro group.
• Compound (AP1-e) may be obtained by reaction in a solvent such as tetrahydrofuran, ethyl acetate, methanol or ethanol under a hydrogen atmosphere, in the presence of a catalyst such as palladium-carbon.
• compound (AP1-e) may be obtained by conducting the reaction in a solvent such as hydrated methanol or hydrated ethanol in the presence of ammonium chloride, with addition of iron at the reflux temperature of the solvent.
• R1 represents hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted alkoxy.
• Step 1 represents a step of bromination of the para-position relative to the phenolic hydroxyl group. Reaction with bromine is conducted in a solvent such as methanol, ethanol or chloroform. Alternatively, compound (AP2-a) may be obtained by reaction with N-bromosuccinimide in a solvent such as acetonitrile or dimethylformamide.
• Step 2 represents a step of nitration.
• Compound (AP2-b) may be obtained by reaction with fuming nitric acid or concentrated nitric acid in a solvent such as toluene, hexane, ether or acetic anhydride. Alternatively, the reaction may be conducted by generating nitric acid from sodium nitrate and hydrochloric acid.
• Step 3 represents a step of introducing a substituent R2 with any of various structures at the hydroxyl group of compound (AP2-b).
• Compound (AP2-c) may be obtained by reaction with a halide, mesylate or tosylate in a solvent such as dimethylformamide, acetonitrile, tetrahydrofuran, dichloromethane or acetone, in the presence of a base such as potassium carbonate, cesium carbonate, sodium hydrogencarbonate, trialkylamine, a pyridine derivative or sodium hydride.
• R2 has the same definition as R6 in Step 1 of Production Process MO.
• Step 4 represents a step of reduction of the nitro group.
• Compound (AP2-d) may also be obtained by conducting the reaction in a solvent such as hydrated methanol or hydrated ethanol in the presence of ammonium chloride, with addition of iron at the reflux temperature of the solvent.
• Production Processes PP to BOL are general production processes for aminophenol derivatives using compounds synthesized by Production Process AP as the starting materials.
• Production Process PP is an exemplary synthetic method for a piperazine derivative.
• Step 1 represents a step of treating the amino group of compound (PP-a) with bis(chloroethyl)amine hydrochloride to form a piperazine ring.
• compound (PP-a) is reacted with bis(chloroethyl)amine hydrochloride in 1,2-dichlorobenzene while heating to reflux, and the reaction is conducted while removing the generated hydrogen chloride gas to yield compound (PP-b).
• R1 represents hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkoxy, optionally substituted alkylamino, etc.
• R2 represents hydrogen, optionally substituted alkyl, etc.
• Step 2 represents a step of introducing substituent R3 at the secondary amine position of the piperazine of compound (PP-b).
• R3-X1 halogen
• R3 of reagent R3-X1 represents optionally substituted alkyl, optionally substituted alkyl having cyano on the end or a branch, alkyl having protected or substituted carboxylic acid on the end or a branch, alkyl having protected or substituted hydroxyl on the end or a branch, alkyl having protected or substituted amino on the end or a branch, optionally substituted sulfonyl, optionally substituted acyl, or optionally substituted carbamoyl.
• the reagent used to introduce substituent R3 into compound (PP-b) may be, instead of R3-X1 mentioned above, di-t-butyl dicarbonate or optionally substituted isocyanate.
• Compound (PP-b) may be subjected to reductive amination using an optionally substituted aldehyde or ketone and sodium triacetoxyborohydride or sodium cyanoborohydride for introduction of substituent R3.
• Compound (PP-c) obtained by this Production Process may be converted to the final target compound by Production Process A.
• Production Process MO is an exemplary production process for a heterocyclic amino derivative.
• Step 1 represents a step of treating the amino group of compound (MO-a) with a reagent represented by Z1-Y1-Y2-Y3-Z2 to form a nitrogen-containing ring.
• Compound (MO-b) may be obtained by reacting compound (MO-a) with reagent Z1-Y1-Y2-Y3-Z2 in an appropriate solvent such as dimethylformamide, tetrahydrofuran or dichloromethane, in the presence of an inorganic base such as potassium carbonate, sodium hydrogencarbonate or cesium carbonate or in the presence of an organic base such as trialkylamine or a pyridine derivative.
• an inorganic base such as potassium carbonate, sodium hydrogencarbonate or cesium carbonate
• organic base such as trialkylamine or a pyridine derivative.
• Z1 and Z2 in the reagent Z1-Y1-Y2-Y3-Z2 represent leaving groups such as halogen or sulfonate.
• Y1 and Y3 represent methylene optionally substituted with alkyl, alkoxy or the like, carbonyl, carboxyl, sulfonyl or amide.
• Elements to form the main chain at the portion represented by —Y2-in include carbon, oxygen, nitrogen and sulfur, and there are no particular restrictions on the length of the chain.
• the element forming the —Y2-main chain may also have as a substituent optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkoxyalkyl, optionally substituted hydroxyalkyl, hydroxy, carbonyl, optionally protected or substituted carboxyl, optionally protected or substituted carboxyalkyl, optionally protected or substituted amine, optionally protected or substituted aminoalkyl, etc.
• An oxo group may also be present on the —Y2-main chain to form carbonyl, sulfonyl or sulfinyl together with carbon or sulfur on the main chain.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R6 represents optionally substituted alkyl, a protecting group for hydroxyl, such as methoxymethyl, tetrahydropyranyl or trialkylsilyl, or alternatively alkyl having cyano at the end or a branch, alkyl having protected or substituted carboxylic acid on the end or a branch, arylalkyl having protected or substituted carboxylic acid on the end or a branch, alkyl having protected or substituted hydroxyl on the end or a branch, arylalkyl having protected or substituted hydroxyl on the end or a branch, alkyl having protected or substituted amino on the end or a branch, arylalkyl having protected or substituted amino on the end or a branch, optionally substituted sulfonyl, optionally substituted acyl, optionally substituted carbamoyl, etc.
• a protecting group for hydroxyl such as methoxymethyl, t
• Step 2 represents a step of deprotection when R6 of compound (MO-b) is a protecting group for the phenolic hydroxyl group.
• R6 of compound (MO-b) is a protecting group for the phenolic hydroxyl group.
• compound (MO-c) wherein R6 is methoxymethyl may be obtained by treating compound (MO-b) with an acidic mixed solvent such as 5 N hydrochloric acid/acetone or 10% aqueous perchloric acid/tetrahydrofuran.
• Step 3 represents a step of introducing a new substituent R7 at the phenolic hydroxyl group of compound (MO-c).
• R7 has the same definition as R6 in Step 1 of Production Process MO.
• Compound (MO-d) wherein X2 of reagent R7-X2 described below is a leaving group such as halogen or sulfonate may be synthesized in the following manner.
• Compound (MO-d) may be obtained by reacting compound (MO-c) with reagent R7-X2 in an appropriate solvent such as dimethylformamide, acetonitrile, diethyl ether, tetrahydrofuran or dichloromethane, in the presence of an inorganic base such as potassium carbonate, sodium hydrogencarbonate or cesium carbonate or in the presence of an organic base such as trialkylamine or a pyridine derivative, or in the presence of sodium hydride.
• an inorganic base such as potassium carbonate, sodium hydrogencarbonate or cesium carbonate
• organic base such as trialkylamine or a pyridine derivative
• Compound (MO-d) wherein R7 is methyl may be obtained at a high yield by reacting compound (MO-c) with diazomethane in diethyl ether or with trimethylsilyldiazomethane in acetonitrile-diisopropylethylamine-methanol.
• Compound (MO-d) wherein X2 in reagent R7-X2 is hydroxyl may be obtained by reacting compound (MO-c) with reagent R7-X2 by the publicly known Mitsunobu reaction in an appropriate solvent such as tetrahydrofuran or toluene.
• R6 and R7 may sometimes undergo conversion to a structure which is not defined herein by a method easily predictable by a person skilled in the art at an appropriate stage after introduction.
• the —N—Y1-Y2-Y3(—N) portion obtained by cyclization in Step 1 may sometimes also undergo conversion to a structure which is not defined herein. (Conversion of the —N—Y1-Y2-Y3(—N) portion is described in some of the following Production Process examples).
• Compounds (MO-b), (MO-c) and (MO-d) obtained in this Production Process may be converted to the final target compounds by Production Process A.
• Production Process PR is an exemplary synthetic method for pyrrolidine derivatives.
• Scheme PR-1 is an exemplary production scheme whereby the —N—Y1-Y2-Y3(—N) portion obtained by cyclization in Step 1 of Production Process MO may undergo additional structural conversion.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R10 and R11 have the same definitions as R6 and R7 in Production Process MO.
• methoxymethyl is mentioned as a protecting group for the phenolic hydroxyl group of compounds (PR1-a) and (PR1-b), there is no limitation to methoxymethyl.
• Step 1 represents a step of introducing a substituent R10 at the hydroxyl group of compound (PR1-a).
• the reaction is conducted using reagent R10-X3 in an appropriate alkaline hydrated organic solvent, in the presence of a phase transfer catalyst.
• compound (PR1-b) is obtained by reaction of reagent R10-X3 with compound (PR1-a) in a mixture of 50% aqueous sodium hydroxide and toluene in the presence of tetrabutylammonium bromide.
• X3 is a leaving group such as halogen or sulfonate.
• Step 2 represents a step of treating compound (PR1-b) in the same manner as Step 2 of Production Process MO to yield compound (PR1-c).
• Step 3 represents a step of introducing a new substituent R11 at the phenolic hydroxyl group of compound (PR1-c).
• Compound (PR1-c) may be treated in the same manner as for introduction of R7 in Step 3 of Production Process MO to yield R11 introduced compound (PR1-d).
• Step 4 represents a step of treating compound (PR1-a) in the same manner as Step 2 of Production Process MO to yield compound (PR1-e).
• Step 5 represents a step of selectively introducing substituent R11 only at the phenolic hydroxyl group of compound (PR1-e). Utilizing the difference in reactivity between the two hydroxyl groups of compound (PR1-e), treatment may be carried out in the same manner as for introduction of R7 in Step 3 of Production Process MO to yield R11 introduced compound (PR1-f).
• Step 6 represents a step of treating compound (PR1-f) in the same manner as Step 1 of this Scheme PR-1 to yield compound (PR1-d).
• Scheme PR-2 is another exemplary production scheme whereby the —N—Y1-Y2-Y3(—N) portion obtained by cyclization in Step 1 of Production Process MO may undergo additional structural conversion.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R15 and R20 have the same definitions as R6 and R7 in Production Process MO.
• Step 1 represents a step of replacing the hydroxyl group of compound (PR1-a) with a substituent R14 (F or CN).
• R14 is fluoro
• DAST diethylaminosulfur trifluoride
• R14 is cyano
• the hydroxyl group of compound (PR1-a) may first be converted to a leaving group with an acyl chloride reagent such as methanesulfonyl chloride in an appropriate solvent such as dichloromethane, in the presence of a base such as triethylamine.
• a hydrogen cyanide salt may then be reacted with this intermediate to introduce a cyano group.
• Step 5 represents a step of esterifying or amidating the carboxylic acid group of compound (PR2-d) for introduction of a substituent R18 by common methods.
• the carboxylic acid group of compound (PR2-d) may be converted to an active species by a common method such as an acid mixing method using a chloroformic acid ester or an acid chloride method using oxalyl chloride, and then reacted with an alcohol or amine for conversion to (PR2-e).
• (PR2-d) may be esterified by reaction with the corresponding alkyl halide reagent in the presence of an appropriate base or by reaction with di-tert-butyl dicarbonate in tert-butyl alcohol in the presence of dimethylaminopyridine.
• Compound (PR2-d) may also be subjected to dehydration reaction using an alcohol or amine and a peptide-forming condensing agent, for conversion to compound (PR2-e).
• the synthesis may also be carried out by other suitable known reactions.
• R18 represents amino or alkoxy.
• the methyl orthoformate is reacted with the carbonyl group in methanol in the presence of an acid catalyst such as camphorsulfonic acid or p-toluenesulfonic acid and Molecular Sieve 3A, to yield compound (PR2-f).
• an acid catalyst such as camphorsulfonic acid or p-toluenesulfonic acid and Molecular Sieve 3A
• Step 7 represents a step of reducing the ester group of compound (PR2-f) for conversion to a hydroxymethyl group, and then selectively deprotecting only the ketal protection of the carbonyl group of the acetophenone.
• compound (PR2-f) is reacted with an ester-reducing reagent such as lithium aluminum hydride in an appropriate solvent such as tetrahydrofuran or diethyl ether, for conversion to a hydroxymethyl group.
• Step 8 represents a step of converting the hydroxyl group of compound (PR2-g) to substituent R19 (cyano or various alkoxy).
• R19 is cyano
• treatment is carried out in the same manner as for conversion in Step 1 when R14 is cyano, to yield compound (PR2-h) wherein hydroxymethyl of compound (PR2-g) may be converted to cyanomethyl, in which case R19 represents cyano.
• R19 is alkoxy
• compound (PR2-g) is treated in the same manner as Step 1 of Scheme PR-1 to yield compound (PR2-h) for conversion to alkoxy, in which case R19 has the same definition as OR10 in Scheme PR-1.
• Step 9 represents a step of deprotecting the methoxymethyl group serving as the protecting group for the phenolic hydroxyl group of compound (PR2-h), and then introducing a substituent R20.
• compound (PR2-h) is treated in the same manner as Step 2 of Production Process MO to remove the methoxymethyl group. It is then treated in the same manner as for introduction of R7 in Step 3 of Production Process MO to yield compound R20 introduced (PR2-i).
• Scheme PR-3 is an exemplary production scheme whereby the —N—Y1-Y2-Y3(—N) portion obtained by cyclization in Step 1 of Production Process MO may undergo additional structural conversion.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R23, R24 and R25 have the same definitions as R6 and R7 in Production Process MO.
• Step 1 represents a step of treating compound (PR3-a) in the same manner as Step 1 of Scheme PR-1 to yield compound (PR3-b) having one substituent R24 introduced therein and compound (PR3-c) having two substituents R24 introduced therein.
• R24 is methoxymethyl or the like
• an excess of methoxymethyl chloride may be reacted with compound (PR3-a) in the presence of diisopropylethylamine to yield compounds (PR3-b) and (PR3-c).
• Compounds (PR3-b) and (PR3-c) may be separated by silica gel column chromatography.
• Step 2 represents a step of treating compound (PR3-b) in the same manner as Step 1 to yield compound (PR3-d) having a newly introduced substituent R25.
• Step 3 represents a step of stereoinversion of the hydroxyl group of compound (PR3-b) to yield compound (PR3-e).
• Compound (PR3-b) is reacted with m-nitrobenzenesulfonyl chloride in dichloromethane in the presence of triethylamine and dimethylaminopyridine. It is then treated with cesium acetate while heating in dimethylsulfoxide to yield a hydroxyl-inverted acetate. This is treated with potassium carbonate in methanol to yield hydroxyl-inverted compound (PR3-e).
• Compounds (PR3-b), (PR3-c) and (PR3-d) obtained in Scheme PR-3 may be converted to the final target compounds by Production Process A.
• Compound (PR3-e) may also be treated in the same manner as Step 2 of this scheme and then converted to the final target compound by Production Process A.
• Scheme PR-4 is an exemplary production scheme whereby the —N—Y1-Y2-Y3(—N) portion obtained by cyclization in Step 1 of Production Process MO may undergo additional structural conversion.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R26 has the same definition as R6 and R7 in Production Process MO.
• Step 1 represents a step of treating compound (PR4-a) with Lawesson's reagent while heating in 1,4-dioxane to yield a thioamide (PR4-b).
• Step 2 represents a step of treating compound (PR4-b) with ethyl O-trifluoromethanesulfonylhydroxyacetate, triphenylphosphine and triethylamine to yield compound (PR4-c).
• Step 3 represents a step of reacting compound (PR4-c) with sodium triacetoxyborohydride in 1,2-dichloroethane in the presence of acetic acid for reduction of the enamine to yield compound (PR4-d).
• Step 4 represents a step of converting compound (PR4-d) to a carboxylic acid derivative (PR4-e) under appropriate conditions such that substituent R26 is not affected. Generally, it is treated with aqueous sodium hydroxide or aqueous lithium hydroxide in an alcohol or an alcohol-tetrahydrofuran mixed solvent for alkali hydrolysis to yield compound (PR4-e).
• Step 5 represents a step of treating compound (PR4-e) with di-tert-butyl dicarbonate in tert-butanol in the presence of dimethylaminopyridine to yield the tert-butylesterified compound (PR4-f).
• Scheme PR-5 is an exemplary production scheme whereby the —N—Y1-Y2-Y3 (—N) portion obtained by cyclization in Step 1 of Production Process MO may undergo additional structural conversion.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R27 has the same definition as R6 and R7 in Production Process MO.
• Step 1 represents a step of treating compound (PR5-a) with a catalytic amount of rhodium (II) acetate dimer and the known reagent diethyl diazomalonate while heating in toluene, to yield compound (PR5-b).
• Step 2 represents a step of treating compound (PR5-b) with equivalents of sodium ethoxide and ethyl acrylate while heating in ethanol to yield the cyclized compound (PR5-c).
• Step 3 represents a step of treating compound (PR5-c) with 5 N hydrochloric acid while heating in ethanol to yield compound (PR5-d) having the methoxymethyl protecting group removed.
• Step 4 represents a step of converting compound (PR5-d) to compound (PR5-e) having a newly introduced substituent R27.
• Compound (PR5-e) may be obtained by treatment in the same manner as for introduction of R7 in Step 3 of Production Process MO.
• Step 5 represents a step of treating compound (PR5-e) with 1,2-bis(trimethylsiloxy)ethane and triethylsilyltriflate in dichloromethane to yield compound (PR5-f), wherein the acetyl carbonyl of compound (PR5-e) is ketal-protected.
• Step 6 represents a step of reducing the lactam carbonyl of compound (PR5-f) for conversion to methylene.
• Compound (PR5-f) may be reacted with carbonylhydridotris(triphenylphosphine)rhodium(I) and diphenylsilane in an appropriate solvent such as tetrahydrofuran to yield compound (PR5-g).
• Step 7 represents a step of reacting compound (PR5-g) in 5% hydrochloric acid-tetrahydrofuran to yield the ketal-deprotected compound (PR5-h).
• This Production Process PS is an exemplary synthetic method for a piperidine derivative.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R28 and R30 have the same definitions as R6 and R7 in Production Process MO.
• Step 1 represents a step of reacting compound (PS-a) with formaldehyde to produce an imine, and then subjecting it to hetero Diels-Alder reaction with a diene having an enol ether structure to form an oxopiperidine ring.
• Compound (PS-a) is reacted with 37% formalin in dichloromethane in the presence of magnesium sulfate to produce an imine, and the reaction mixture is filtered with celite.
• Step 2 represents a step of treating compound (PS-b) with p-toluenesulfonylmethyl isocyanide (TosMIC) in dimethoxyethane-tert-butanol in the presence of potassium tert-butoxide, to yield compound (PS-c) having oxo converted to cyano.
• TosMIC p-toluenesulfonylmethyl isocyanide
• Step 3 represents a step of reacting the carbonyl group of compound (PS-b) with any of various organometallic reagents to yield a tert-alcohol (PS-d) having an added substituent R29.
• compound (PS-b) may be reacted with methylmagnesium bromide in diethyl ether to yield compound (PS-d) having an added methyl group.
• R29 represents alkyl, alkenyl or alkynyl.
• Step 4 represents a step of treating compound (PS-b) with a reducing agent for conversion to an alcohol compound (PS-e).
• a reducing agent for conversion to an alcohol compound (PS-e).
• Various reducing agents may be used, and treatment with sodium borohydride in a methanol-dichloromethane mixed solvent is preferred to yield compound (PS-e).
• Step 5 represents a step of treating compound (PS-e) in the same manner as Step 1 of Scheme PR-1 of Production Process PR to yield compound (PS-f) having a newly introduced substituent R30 at the hydroxyl group.
• Substituent R30 has the same definition as R6 and R7 in Production Process MO.
• Step 6 represents a step of Horner-Emmons reaction at the carbonyl group of compound (PS-b) to yield the carbon-carbon bond formed unsaturated ester (PS-g).
• PS-b carbon-carbon bond formed unsaturated ester
• PS-g unsaturated ester
• Step 7 represents a step of 1,4-reduction of the unsaturated ester.
• Compound (PS-g) may be treated with sodium borohydride in a dichloromethane-methanol mixed solvent in the presence of a catalytic amount of nickel (II) chloride-6 hydrate, or reacted with magnesium in methanol for selective 1,4-reduction of the unsaturated ester to yield compound (PS-h).
• a piperidine derivative may also be synthesized by the following Steps 8 to 10.
• Step 8 represents a step of treating compound (PS-i) in the same manner as Step 1 to yield compound (PS-j), with simultaneous formation of an oxopiperidine ring and deprotection of the methoxymethyl group serving as the phenolic hydroxyl group-protecting group.
• Step 9 represents a step of treating compound (PS-j) in the same manner as for introduction of R7 in Step 3 of Production Process MO, to yield compound (PS-k) substituted with substituent R28.
• Step 10 represents a step of selectively protecting the carbonyl group of the acetophenone of compound (PS-k). After adding compound (PS-k) to tetrahydrofuran, adding triethylamine and cooling to ⁇ 70° C., the mixture is treated with tert-butyldimethylsilyl trifluoromethanesulfonate. The state of the reaction is periodically examined by thin-layer column chromatography, and the temperature is gradually raised if necessary. Water may be added at low temperature to stop the reaction to yield compound (PS-m).
• compound (PS-m) may be treated in the same manner as in Steps 2, 3 and 0.4. Alternatively, it may be converted directly to an acyl bromide according to Production Process A for conversion to the final target compound.
• Compounds (PS-b), (PS-c), (PS-d), (PS-e), (PS-f), (PS-g), (PS-h), (PS-j) and (PS-k) obtained in this Production Process may be converted to the final target compounds by Production Process A.
• This scheme is an exemplary synthesis for an aniline derivative.
• R1 has the same definition as in Step 1 of Production Process PP.
• R31, R32 and R33 have the same definitions as R6 and R7 in Production Process MO.
• Step 1 represents a step of introducing one or two substituents R31 at the amino group of compound (AN1-a).
• Compound (AN1-a) may be treated in approximately the same manner as for introduction of R7 at the hydroxyl group in Step 3 of Production Process MO to yield compounds (AN1-b) and (AN1-c).
• R31 is bonded to the aniline amino group as simple alkyl and not via acyl or sulfonyl (when R31-I or R31-Br is used as the reagent, etc.)
• a prolonged reaction with heating may be necessary to introduce the substituent R31.
• compounds (AN1-b) and (AN1-c) may be easily separated and purified by silica gel column chromatography.
• Step 2 represents a step of treating compound (AN1-b) in the same manner as Step 1 to yield compound (AN1-d) having a newly introduced substituent R32.
• Step 3 represents a step of treating compounds (AN1-c) and (AN1-d) in the same manner as Step 2 of Production Process MO to yield the respective compounds (AN1-e) and (AN1-f).
• Step 4 represents a step of treating compounds (AN1-e) and (AN1-f) in the same manner as for introduction of R7 in Step 3 of Production Process MO to yield the respective compounds (AN1-g) and (AN1-h).
• Step 5 represents a step of using compound (AN1-i) as the starting material for treatment in the same manner as Step 1 to yield compound (AN1-j) having substituents R31 and R33.
• Compound (AN1-g) can also be obtained by this method.
• Step 6 represents a step of treating compound (AN1-j) in the same manner as Step 2 to yield compound (AN1-h).
• Step 7 represents a step of treating compound (AN1-i) in the same manner as the ketalizing reaction of Step 6 in Scheme PR-2, to yield compound (AN1-k).
• Step 8 represents a step of reductive amination of compound (AN1-k) using an aldehyde or ketone (represented by R34—(C ⁇ O)—R35) and a reducing agent to obtain compound (AN1-m).
• Compound (AN1-k) may be reacted with sodium cyanoborohydride in a methanol-acetic acid mixed solvent or reacted with sodium triacetoxyborohydride in a 1,2-dichloroethane-acetic acid mixed solvent, to directly yield compound (AN1-m) having the ketal protecting group also deprotected.
• Either R34 and R35 may be hydrogen, or R34 and R35 may together form a ring.
• Step 9 represents a step of reductive amination of compound (AN1-i) without ketal protection, using an aldehyde or ketone (represented by R34—(C ⁇ O)—R35) and a reducing agent to yield compound (AN1-m). Reaction will usually be conducted with sodium triacetoxyborohydride in a 1,2-dichloroethane-acetic acid mixed solvent.
• Scheme AN-2 is an exemplary synthetic method for further structural conversion of the substituents on the aniline nitrogen of the intermediate synthesized in Scheme AN-1.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R36 has the same definition as R6 and R7 in Production Process MO.
• Either or both R37 and R38 may form an amide bond with the aniline nitrogen, or the substituents may have ester structures.
• One of the substituents on the aniline nitrogen of the starting material (AN2-a) may be hydrogen.
• Step 1 represents a step of treating compound (AN2-a) in the same manner as the ketalizing reaction of Step 6 in Scheme PR-2 of Production Process PR, to yield compound (AN2-b) having the carbonyl group protected.
• Step 2 represents a step of treating compound (AN2-b) with a reducing agent for conversion of amide to methyleneamino (from —N—CO— to —N—CH2-), or of an ester to an alcohol (from —CO—O— to —CH2-OH, from —O—CO— to —OH).
• compound (AN2-b) is treated with lithium aluminum hydride in diethyl ether to yield compound (AN2-c).
• Substituents R39 and R40 are defined as the structures resulting after this conversion of R37 and R38.
• Step 3 represents a step of treating compound (AN2-c) in the same manner as the ketal deprotection reaction of Step 7 in Scheme PR-2, to yield compound (AN2-d).
• Step 4 represents a step carried out only when compound (AN2-d) has a hydroxyl group on substituent R39 or R40, and here a new substituent is introduced at the hydroxyl group to yield compound (AN2-e) by conversion to substituents R41 and R42.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 represents hydrogen, optionally substituted alkyl or the like.
• R3 represents hydrogen, halogeno, oxo, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted acyl, optionally substituted carboxyl or optionally substituted carbamoyl.
• Step 1 represents a step of acylation of the amino group.
• Compound (BO1-b) may be obtained either by reaction with an acyl chloride at room temperature in a solvent such as tetrahydrofuran, methylene chloride or acetonitrile in the presence of a base such as pyridine or triethylamine, or by reaction with an acid anhydride in a pyridine solution.
• Step 2 represents a step of deprotection of the methoxymethyl group protecting the alcohol.
• Compound (BO1-c) may be obtained by reaction with dilute aqueous hydrochloric acid and 10% aqueous perchloric acid in a solvent such as tetrahydrofuran or acetone at room temperature.
• Step 3 represents a step of alkylation of the hydroxyl group and the amino group.
• Compound (BO1-d) may be obtained by reaction with a dihalide, dimesylate or ditosylate in a dimethylformamide solution in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride, while heating from room temperature to 150° C.
• Step 4 represents a step of deacylation.
• Compound (BO1-e) may be obtained either by reaction with an aqueous sodium hydroxide solution in a solvent such as methanol, ethanol or tetrahydrofuran, at room temperature to the reflux temperature of the solvent, or by reaction in an aqueous hydrochloric acid solution at room temperature to the reflux temperature of the solvent.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 has the same definition as R3 in Scheme BO-1.
• Step 1 represents a step of alkylation of the hydroxyl group.
• Compound (BO2-b) may be obtained by reaction with a dihalide, dimesylate or ditosylate in a dimethylformamide solution while heating from room temperature to 150° C.
• Step 2 represents a step of forming an oxazine ring. Reaction is conducted with a dihalide, dimesylate or ditosylate in a dimethylformamide solution in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride, while heating from room temperature to 150° C. Reaction is then conducted at room temperature in an ethanol or methanol solution in the presence of a catalytic amount of palladium-carbon in a hydrogen atmosphere to yield compound (BO2-c).
• a base such as potassium carbonate, cesium carbonate or sodium hydride
• R1 represents hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted alkoxy.
• R2 represents hydrogen, optionally substituted alkyl, alkyl having cyano at the end or a branch, optionally substituted alkoxy, optionally substituted arylalkyl, optionally substituted acyl, optionally substituted sulfonyl, optionally substituted carbamoyl or optionally substituted carboxyl.
• Step 1 represents a step of alkylating, acylating, substituted carbamoylating or urethanating the amino group, by any of the following methods 1 to 4.
• Compound (BO3-b) may be obtained by reaction with a halide, mesylate or tosylate in a dimethylformamide solution in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride, while heating from room temperature to 150° C.
• a base such as potassium carbonate, cesium carbonate or sodium hydride
• Compound (BO3-b) may be obtained either by reaction with an acyl chloride, sulfonyl chloride or isocyanate at room temperature in a solvent such as tetrahydrofuran, methylene chloride or acetonitrile, in the presence of a base such as pyridine or triethylamine, or by reaction with an acid anhydride in a pyridine solution.
• a solvent such as tetrahydrofuran, methylene chloride or acetonitrile
• a base such as pyridine or triethylamine
• Compound (BO3-b) may be obtained by reaction with ethyl N-(1-cyano)iminoformate in methanol or ethanol in the presence of a catalytic amount of 4-dimethylaminopyridine, at room temperature to the reflux temperature of the solvent.
• Compound (BO3-b) may be obtained by reaction with trimethyl orthoformate or triethyl orthoformate in methanol or ethanol in the presence of a catalytic amount of p-toluenesulfonic acid or camphorsulfonic acid, ketal protection of the acetyl group and introduction of different substituents by methods 1 to 3 above, followed by deprotection under acidic conditions.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 has the same definition as R3 in Scheme BO-1.
• R3 has the same definition as R2 in Scheme BO-3.
• Step 1 represents a step of alkylation.
• Compound (B04-b) may be obtained by the method described in Tawada, H., Sugiyama, Y., Ikeda, H., Yamamoto, Y., Meguro, K; Chem. Pharm.
• Step 2 represents a step of alkylating, acylating, substituted carbamoylating or urethanating the amino group.
• Compound (BO4-c) may be obtained by treatment in the same manner as Step 1 of Scheme BO-3.
• Compounds (BO4-b) and (BO4-c) obtained in Scheme BO-4 may be converted to the final target compound by Production Process A.
• Production Process BOL is an exemplary synthetic method for a benzoxazole derivative.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 represents hydrogen, optionally substituted alkyl or optionally substituted alkoxy.
• Step 1 represents a step of forming an oxazole ring.
• Compound (BOL-b) may be obtained by reaction with an acid chloride in a solvent such as tetrahydrofuran, methylene chloride or acetonitrile in the presence of a base such as triethylamine, followed by reaction with dilute aqueous hydrochloric acid or p-toluenesulfonic acid in a solvent such as ethanol, methanol, tetrahydrofuran or methyl ethyl ketone.
• a solvent such as tetrahydrofuran, methylene chloride or acetonitrile
• a base such as triethylamine
• the benzoxazoleethanone derivative (BOL-b) obtained in Production Process BOL may be converted to the final compound by Production Process A.
• Schemes CA-1, 2 and 3 below in Production Process CA are general synthesis methods for catechol derivatives.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2, R3 and R4 have the same definitions as R6 and R7 in Production Process MO.
• Step 1 represents a step of methoxymethylating the hydroxyl group of compound (CA1-a).
• Compound (CA1-b) is obtained by reaction of compound (CA1-a) and sodium hydride in dimethylformamide at room temperature, followed by reaction with methoxymethyl chloride (MOM-Cl).
• Step 2 represents a step of introducing a formyl group by ortholithiation utilizing the substituent effect of the methoxymethyl group of compound (CA1-b).
• the orthoformylated compound (CA1-c) is obtained by treatment of compound (CA1-b) with n-butyllithium in diethyl ether while cooling on ice in the presence of tetramethylethylenediamine, followed by treatment with a formylating agent such as dimethylformamide or N-formylmorpholine.
• Step 3 represents a step of brominating the para-position relative to the methoxymethyl group of compound (CA1-c).
• Compound (CA1-d) is obtained by reaction of compound (CA1-c) with bromine in methanol at room temperature, and removal of the methoxymethyl group by the hydrogen bromide generated in the system.
• Step 4 represents a step of introducing any of various substituents at the hydroxyl group of compound (CA1-d).
• Compound (CA1-e) is obtained by the same method as for introduction of R7 in Step 3 of Production Process MO.
• Step 5 represents a step of oxidative conversion of the formyl group to a hydroxyl group.
• Compound (CA1-f) is obtained by reacting compound (CA1-e) with m-chloroperbenzoic acid in dichloromethane at room temperature or with heating, and then hydrolyzing the purified ester using potassium carbonate in methanol.
• Step 6 represents a step of obtaining R3 introduced compound (CA1-g) by the same method as in Step 4 of Scheme CA-1.
• Step 7 represents a step of conversion to substituent R4 when R2 is a hydroxyl-protecting group.
• Compound (CA1-h) is obtained in the same manner as the continuous treatment in Steps 2 and 3 of Production Process MO.
• Scheme CA-2 is an exemplary synthetic method for a cyclic catechol derivative.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 and R4 have the same definitions as R6 and R7 in Production Process MO.
• Step 8 represents a step of conversion to a catechol when R2 is an eliminable hydroxyl-protecting group.
• R2 is methoxymethyl
• a diol (catechol) (CA2-a) is obtained by treating compound (CA1-f) with 6 N hydrochloric acid.
• Step 9 represents a step of cyclizing the catechol by alkylation.
• Compound (CA2-a) is reacted with a 1,2-dibromoethyl derivative in a solvent such as dimethylformamide, acetonitrile or acetone in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride, to yield a fused dioxane ring (CA2-b).
• Compound (CA2-a) may also be treated with acetone in the presence of phosphorus pentaoxide to yield a 5-membered cyclic product (CA2-b) as an acetonide.
• Compound (CA2-b) obtained in this Scheme CA-2 may be converted to the final target compound by Production Process A.
• Scheme CA-3 is an exemplary synthetic method for a disubstituted catechol derivative.
• R5 and R6 have the same definitions as R6 and R7 in Production Process MO.
• Step 10 represents a step of obtaining compound (CA3-b) by the same method as in Step 4 of Scheme CA-1 using the catechol (CA3-a) as the starting material.
• Step 11 represents a step of treating compound (CA3-b) by the same method as in Step 3 of Scheme CA-1 to yield compound (CA3-c) which is selectively brominated at the para-position relative to the non-substituted hydroxyl group.
• Step 12 represents a step of obtaining R6 introduced compound (CA3-d) by the same method as in Step 4 of Scheme CA-1.
• Compound (CA3-d) obtained by Scheme CA-3 may be converted to the final target compound by Production Process A.
• R1 and R2 have the same definition as R1 in Step 1 of Production Process PP.
• R3 has the same definition as R6 and R7 in Production Process MO.
• Step 1 represents a step of Friedel-Crafts acylation.
• Compound (CO1-b) is obtained by reaction with acetyl chloride in methylene chloride or toluene in the presence of a Lewis acid such as aluminum chloride, zinc chloride or tin (II) chloride, at ⁇ 70° C. to room temperature.
• a Lewis acid such as aluminum chloride, zinc chloride or tin (II) chloride
• Step 2 represents a step of alkylation, carbonation, sulfonation or the like.
• Compound (CO1-c) may be obtained by reaction with a halide, mesylate or tosylate in a dimethylformamide solution in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride, while heating from room temperature to 150° C.
• a base such as potassium carbonate, cesium carbonate or sodium hydride
• Compound (CO1-c) may be obtained either by reaction with an acyl chloride, sulfonyl chloride or isocyanate in a solvent such as tetrahydrofuran, methylene chloride or acetonitrile in the presence of a base such as pyridine or triethylamine, at ⁇ 15° C. to room temperature, or by reaction with an acid anhydride in a pyridine solution.
• a solvent such as tetrahydrofuran, methylene chloride or acetonitrile
• a base such as pyridine or triethylamine
• Compound (CO1-c) may also be obtained by reaction with phenyl chloroformate in a solvent such as tetrahydrofuran, methylene chloride or acetonitrile in the presence of a base such as pyridine or triethylamine, followed by reaction with an amine.
• a solvent such as tetrahydrofuran, methylene chloride or acetonitrile
• a base such as pyridine or triethylamine
• Compounds (CO1-b) and (CO1-c) obtained in this Scheme CO-1 may be converted to the final target compounds by Production Process A.
• Compound (CO1-a) may also be used in the conversion of compound (A4-c) in Scheme A-4 of Production Process A.
• Scheme CO-2 is an exemplary synthetic method for an aromatic-substituted benzene derivative.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 has the same definition as R6 and R7 in Production Process MO.
• R3 represents an aromatic ring.
• Step 1 represents a step of introducing an aromatic substituent using the Stille coupling method.
• Compound (CO2-b) is obtained by reaction with aromatic-substituted tributyltin in a solvent such as toluene or xylene under a nitrogen atmosphere in the presence of a catalytic amount of tetrakis(triphenylphosphine)palladium, at the reflux temperature of the solvent.
• Scheme CO-3 is an exemplary synthetic method for a benzylamine derivative.
• R1 and R3 have the same definition as R1 in Step 1 of Production Process PP.
• R2 and R2′ have the same definitions as R6 and R7 in Production Process MO.
• R4 and R5 have the same definition as R2 in Scheme BO-3.
• R4 and R5 may also form a ring together.
• X represents hydroxyl or sulfonate.
• Step 1 represents a step of introducing an alkyl halide.
• Compound (CO3-b) is obtained by reaction with sodium borohydride in methanol or ethanol, followed by reaction with methanesulfonyl chloride or the like in dimethylformamide, in the presence of a base such as pyridine or triethylamine.
• Step 2 represents a step of amination.
• Compound (CO3-c) may be obtained by reaction with an amine in methanol, ethanol, acetonitrile or tetrahydrofuran.
• Compound (CO3-c) may be obtained by reaction with an amine in dimethylformamide in the presence of a base such as potassium carbonate or sodium hydride.
• compound (CO3-c) may be obtained by reaction with diphenylphosphoryl azide in toluene in the presence of a base such as 1,8-diazabicyclo [5.4.0] undec-7-ene to yield an azide, followed by reaction with a trialkylphosphine or triphenylphosphine in tetrahydrofuran-water.
• a base such as 1,8-diazabicyclo [5.4.0] undec-7-ene
• Step 3 represents a step of converting R2 to substituent R2′ when R2 is a hydroxyl-protecting group.
• Compound (CO3-d) is obtained in the same manner as the continuous treatment in Steps 2 and 3 of Production Process MO.
• Scheme CO-4 is an exemplary synthetic method for phenol and phenoxy derivatives by Wittig reaction.
• R1 has the same definition as R1 in Production Process PP.
• R2 and R2′ have the same definitions as R6 and R7 in Production Process Mo.
• R3 represents hydrogen or lower alkyl.
• R4 represents optionally substituted alkyl, optionally substituted carboxyl, cyano or the like.
• Step 1 represents a step of alkylation utilizing Wittig reaction. Reaction is conducted with a phosphorane derivative in methylene chloride or tetrahydrofuran. Alternatively, compound (CO4-b) may be obtained by reaction with a phosphonium salt or phosphonate in tetrahydrofuran or dimethylformamide in the presence of a base such as potassium tert-butoxide or sodium hydride.
• a base such as potassium tert-butoxide or sodium hydride.
• Step 2 represents a step of reducing the olefin.
• Compound (CO4-c) may be obtained by accomplishing reduction by reaction in ethyl acetate, tetrahydrofuran or methanol under a hydrogen atmosphere in the presence of palladium-carbon, or by reaction with magnesium in methanol.
• Step 3 represents a step of conversion to substituent R2′ when R2 is a hydroxyl-protecting group.
• Compound (CO4-d) is obtained in the same manner as the continuous treatment in Steps 2 and 3 of Production Process MO.
• Scheme CO-5 is an exemplary synthetic method for phenol and phenoxy derivatives utilizing Friedel-Crafts reaction.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 represents hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl.
• R3 has the same definition as R6 and R7 in Production Process MO.
• Step 1 represents a step of bromination at the para-position of phenyl. Reaction may be conducted either with bromine in methanol or ethanol or with N-bromosuccinimide in acetonitrile to yield Compound (CO5-a).
• Step 2 represents a step of alkylation by Friedel-Crafts reaction.
• Compound (CO5-b) is obtained by reaction with alkyl mesylate in benzene or dichloroethane in the presence of scandium triflate, by the method described in H. Katsuki et al., Synthesis 603(1999).
• Step 3 represents a step of introducing a substituent R3 at the hydroxyl group.
• Compound (CO5-c) is obtained by treatment in the same manner as for introduction of R7 in Step 3 of Production Process MO.
• Scheme CO-6 is an exemplary synthetic method for carboxylic acid derivatives and benzyl alcohol derivatives.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 represents optionally substituted alkyl and R3 and R4 have the same definitions as R6 and R7 in Production Process MO.
• Step 1 represents a step of introducing a carboxyl group by ortholithiation utilizing the substituent effect of the methoxymethyl group of compound (CA1-b).
• Compound (CO6-a) is obtained by treating compound (CA1-b) with n-butyllithium in diethyl ether in the presence of tetramethylethylenediamine while cooling on ice, and then reacting it with an alkyl dicarbonate.
• Step 2 represents a step of deprotection of the methoxymethyl group serving as the alcohol-protecting group.
• Compound (CO6-b) is obtained by reaction with dilute aqueous hydrochloric acid and 10% aqueous perchloric acid in tetrahydrofuran or acetone at room temperature.
• Step 3 represents a step of introducing a substituent R3 at the hydroxyl group.
• Compound (CO6-c) is obtained by treatment in the same manner as for introduction of R7 in Step 3 of Production Process MO.
• Step 4 represents a step of reduction and alkylation of the carboxyl group.
• Compound (CO6-d) is obtained by reaction with lithium aluminum hydride in diethyl ether or tetrahydrofuran while cooling on ice, followed by the same method as in Step 3.
• Scheme CO-7 is an exemplary synthetic method for phenethyl alcohol derivatives, phenylacetic acid derivatives and benzofuran derivatives.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 and R3 have the same definitions as R6 and R7 in Production Process MO.
• R4 and R5 represent optionally substituted alkyl.
• Step 1 represents a step of introducing a hydroxyl group by Wittig reaction followed by hydroboration reaction.
• the reaction is conducted with methyltriphenylphosphonium bromide in tetrahydrofuran in the presence of potassium tert-butoxide.
• Reaction is then conducted with borane-tetrahydrofuran in tetrahydrofuran and with 30% aqueous hydrogen peroxide to yield compound (CO 7 -a).
• Step 2 represents a step of introducing a substituent R3 at the hydroxyl group.
• Compound (CO7-b) is obtained by treatment in the same manner as for introduction of R7 in Step 3 of Production Process MO.
• Step 3 represents a step of carbon-carbon bond formation.
• Compound (CO7-c) is obtained by reaction with methyl methylthiomethyl sulfoxide in tetrahydrofuran in the presence of Triton B, at the reflux temperature of the solvent, followed by reaction with dilute aqueous hydrochloric acid in methanol or ethanol.
• Step 4 represents a step of oxidation.
• Compound (CO7-c) is obtained by the method described in Mangzho Zhao et al., Tetrahedron Lett. 39, 5323(1998) or the method described in Ryoji Noyori et al., J. Am. Chem. Soc., 119, 12386(1997).
• Step 5 represents a step of forming a furan ring when R2 is hydrogen.
• Compound (CO7-d) is obtained by reaction with a bromoacetic acid ester in dimethylformamide in the presence of potassium carbonate, at the reflux temperature of the solvent.
• Scheme CO-8 is an exemplary synthetic method for 2,3-dihydrobenzofuran derivatives or 2,3-dihydrobenzothiophene derivatives.
• R1 has the same definition as R1 in Step 1 of Production Process PP.
• R2 and R3 represent hydrogen, optionally substituted alkyl or optionally substituted alkoxy.
• Step 1 represents a step of alkylation of the hydroxyl group.
• Compound (CO8-b) is obtained by reaction with an allyl halide, allyl mesylate or allyl tosylate in a solvent such as dimethylformamide, acetonitrile or acetone, in the presence of sodium iodide and in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride, according to the method described in J. M. Janusz et al., J. Med. Chem. 41, 1112(1998).
• Step 2 represents a step of forming a furan or thiophene ring.
• Compound (CO8-c) is obtained by the method described in J. M. Janusz et al., J. Med. Chem. 41, 1112(1998), or by reaction at 210° C. in magnesium chloride.
• Step 3 represents a step of Friedel-Craft acylation.
• Compound (CO8-d) is obtained by reaction with acetyl chloride in methylene chloride or toluene in the presence of a Lewis acid such as aluminum chloride, zinc chloride or tin (II) chloride, at ⁇ 70° C. to room temperature.
• a Lewis acid such as aluminum chloride, zinc chloride or tin (II) chloride
• Step 4 represents a step of bromination by reaction with bromine in methanol or ethanol.
• compounds (CO8-e) and (CO8-g) are obtained by reaction with N-bromosuccinimide in acetonitrile or dimethylformamide.
• Step 5 represents a step of forming a furan or thiophene ring.
• Compound (CO8-g) is obtained by reaction with sodium borohydride at 75° C. in dimethylacetamide in the presence of cyclopentadienyldichlorotitanium, by the method described in J. Schwaltz et al., J. Org. Chem. 59, 940(1994).
• Scheme CO-9 is an exemplary synthetic method for carboxylic acid derivatives.
• R1, R2, R3 and R4 represent hydrogen or optionally substituted alkyl.
• Step 1 represents a step of alkylation.
• Compound (CO9-b) is obtained by reaction with an alkyl halide, mesylate or tosylate in tetrahydrofuran or dimethylformamide, in the presence of potassium tert-butoxide or sodium hydride.
• Step 2 represents a step of reduction.
• Compound (CO9-c) is obtained by reaction with diisobutylaluminum hydride in tetrahydrofuran.
• Step 3 represents a step of carbon-carbon bond formation utilizing Wittig reaction.
• the reaction is conducted with a phosphorane derivative in methylene chloride or tetrahydrofuran.
• compound (CO9-d) is obtained by reaction with either a phosphonium salt or phosphonate in tetrahydrofuran or dimethylformamide in the presence of a base such as potassium tert-butoxide or sodium hydride.
• the different isomers (for example, geometric isomers, optical isomers based on asymmetric carbon, stereoisomers, tautomers or the like) obtained for compound (I) according to the invention may be purified and isolated using common separation means such as recrystallization, diastereomer salt methods, enzymatic resolution methods and chromatography methods (for example, thin-layer chromatography, column chromatography, gas chromatography, etc.).
• compounds of the invention represented by formula (I) and salts thereof exhibit excellent thrombin receptor antagonism and especially selective antagonism against PAR1 thrombin receptors.
• compounds of the invention and their salts also exhibit excellent inhibition against platelet aggregation and smooth muscle cell proliferation, with high oral efficacy.
• compounds of the invention and salts thereof can therefore inhibit the cellular response to thrombin which includes platelet aggregation, without inhibiting the catalytic activity of thrombin which converts fibrinogen to fibrin, and can also inhibit vascular smooth muscle proliferation occurring as a result of damage to vascular walls by coronary angioplasty and the like, through selective inhibition of PAR1.
• compounds of the invention and salts thereof may be used to obtain pharmaceutical compositions (formulations) as (i) thrombin receptor antagonists (especially PAR1 thrombin receptor antagonists), (ii) platelet aggregation inhibitors, (iii) smooth muscle cell proliferation inhibitors, (iv) endothelial cell, fibroblast, nephrocyte, osteosarcoma cell, muscle cell, cancer cell and/or glia cell proliferation inhibitors and (v) therapeutic or prophylactic agents for thrombosis, vascular restenosis, deep venous thrombosis, pulmonary embolism, cerebral infarction, heart diseases, disseminated intravascular coagulation, hypertension, inflammatory diseases, rheumatism, asthma, glomerulonephritis, osteoporosis, neurological diseases and/or malignant tumors.
• thrombin receptor antagonists especially PAR1 thrombin receptor antagonists
• platelet aggregation inhibitors e.g., platelet aggregation inhibitor
• compounds of the invention and their salts may be administered for treatment of patients suffering from diseases associated with thrombin receptors, and for treatment of patients suffering from proliferative diseases of, for example, endothelial cell, fibroblast, nephrocyte, osteosarcoma cell, muscle cell, cancer cell and/or glia cell.
• a compound of the invention represented by formula (I) above, a salt thereof or a hydrate of the foregoing may be formulated by a conventional method.
• exemplary dosage forms include tablets, powders, fine particles, granules, coated tablets, capsules, syrups, lozenges, inhalants, suppositories, injections, ointments, eye salves, eye drops, nasal drops, ear drops, paps, lotions and the like.
• Formulations may be prepared with any commonly used excipients, binders, disintegrators, lubricants, coloring agents, corrective coatings, and if necessary, stabilizers, emulsifiers, absorbefacients, surfactants, pH adjustors, preservatives, antioxidants, or the like, in combination with various components that are ordinarily used as materials for pharmaceutical formulations.
• such components include (1) animal and vegetable oils such as soybean oil, beef tallow and synthetic glycerides; (2) hydrocarbons such as liquid paraffin, squalane and solid paraffin; (3) ester oils such as octyldodecyl myristate and isopropyl myristate; (4) higher alcohols such as cetostearyl alcohol and behenyl alcohol; (5) silicone resins; (6) silicone oils; (7) surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil and polyoxyethylene/polyoxypropylene block copolymer; (8) water-soluble polymers such as hydroxyethylcellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone and methylcellulose; (9) lower alcohols such as ethanol and isopropanol
• excipients which may be used include lactose, corn starch, white soft sugar, glucose, mannitol, sorbit, crystalline cellulose and silicon dioxide
• examples of (2) binders which may be used include polyvinyl alcohol, polyvinyl ether, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polypropylene glycol/polyoxyethylene block polymer, meglumine, calcium citrate, dextrin and pectin
• examples of (3) disintegrators which may be used include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogencarbonate, calcium citrate, dextrin, pectin and calcium carboxymethylcellulose
• examples of (4) lubricants which may be used include magnesium stearate, talc, polyethylene glycol, silica and hydrogenated vegetable oils
• An oral formulation may be prepared by combining a compound of the invention or its salt with an excipient, if necessary adding a binder, disintegrator, lubricant, coloring agent, corrective coating or the like, and forming a powder, fine particles, granules, tablets, coated tablets, capsules, etc. by a common method.
• Tablets or granules may, of course, also be coated with a sugar coating, gelatin coating or other type of suitable coating if necessary.
• a liquid formulation such as syrup, injection, eye drops or the like
• a common method may be used for formulation with a pH adjustor, solubilizer, isotonizing agent or the like, as well as a solubilizing aid, stabilizer, buffering agent, suspending agent, antioxidant, etc. if necessary.
• a liquid formulation it may also be lyophilized, and an injection may be administered intravenously, subcutaneously or intramuscularly.
• suspending agents there may be mentioned methylcellulose, polysorbate 80, hydroxyethylcellulose, gum arabic, tragacanth powder, sodium carboxymethylcellulose, polyoxyethylene sorbitan monolaurate and the like; as preferred examples of solubilizing aids there may be mentioned polyoxyethylene hydrogenated castor oil, polysorbate 80, nicotinamide, polyoxyethylene sorbitan monolaurate and the like; as preferred examples of stabilizing agents there may be mentioned sodium sulfite, sodium metasulfite, ether and the like; and as preferred examples of preservatives there may be mentioned methyl p-oxybenzoate, ethyl p-oxybenzoate, sorbic acid, phenol, cresol, chlorocresol, and the like.
• the base materials used may be any raw materials commonly employed in drugs, quasi drugs, cosmetics and the like, and as examples there may be mentioned raw materials such as animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicone oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals, purified water and the like, with addition of pH adjustors, antioxidants, chelating agents, antiseptics and fungicides, coloring agents, aromas and the like if necessary.
• raw materials such as animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicone oils, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals, purified water and the like, with addition of pH adjustors, antioxidants, chelating agents, antiseptics and fungicides, coloring agents, aromas and the like if necessary.
• differentiation-inducing components or other components such as circulation promoters, microbicides, antiphlogistic agents, cell activators, vitamins, amino acids, humectants, keratolytic agents and the like, as necessary.
• the dosage of a drug according to the invention will differ depending on the patient's severity of symptoms, age, gender and body weight, the dosage form and type of salt, drug sensitivity, the specific type of disease, etc.
• the dosage ranges from about 30 ⁇ g to 1000 mg, preferably from 100 ⁇ g to 500 mg and more preferably from 100 ⁇ g to 100 mg per day for adults in the case of oral administration or about 1-3000 ⁇ g/kg and preferably 3-1000 ⁇ g/kg per day for adults in the case of injection, administered once or divided over several times a day.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Rheumatology (AREA)
• Pulmonology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Immunology (AREA)
• Hospice & Palliative Care (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pyrrole Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Indole Compounds (AREA)
• Lubricants (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26613890

Family Applications (6)

Family Applications Before (3)

Family Applications After (2)

Country Status (22)

Cited By (14)

Families Citing this family (85)

Citations (28)

Family Cites Families (35)

• 2002
  • 2002-04-19 BR BR0208985-8A patent/BR0208985A/pt not_active IP Right Cessation
  • 2002-04-19 DE DE60231608T patent/DE60231608D1/de not_active Expired - Lifetime
  • 2002-04-19 US US10/475,188 patent/US7244730B2/en not_active Expired - Fee Related
  • 2002-04-19 ES ES11166172.4T patent/ES2462995T3/es not_active Expired - Lifetime
  • 2002-04-19 PL PL02368109A patent/PL368109A1/xx unknown
  • 2002-04-19 KR KR1020057009505A patent/KR100749795B1/ko not_active IP Right Cessation
  • 2002-04-19 DE DE60233043T patent/DE60233043D1/de not_active Expired - Lifetime
  • 2002-04-19 US US10/475,060 patent/US7476688B2/en not_active Expired - Fee Related
  • 2002-04-19 WO PCT/JP2002/003961 patent/WO2002085855A1/ja active IP Right Grant
  • 2002-04-19 KR KR1020037013674A patent/KR100749794B1/ko not_active IP Right Cessation
  • 2002-04-19 RU RU2003133664/04A patent/RU2270192C2/ru not_active IP Right Cessation
  • 2002-04-19 US US10/475,118 patent/US7304083B2/en not_active Expired - Fee Related
  • 2002-04-19 JP JP2002585396A patent/JP4445201B2/ja not_active Expired - Fee Related
  • 2002-04-19 WO PCT/JP2002/003949 patent/WO2002085850A1/ja active Application Filing
  • 2002-04-19 JP JP2002583382A patent/JP3795458B2/ja not_active Expired - Fee Related
  • 2002-04-19 EP EP11166172.4A patent/EP2385039B1/en not_active Expired - Lifetime
  • 2002-04-19 NZ NZ528820A patent/NZ528820A/en not_active IP Right Cessation
  • 2002-04-19 JP JP2002583377A patent/JP4220249B2/ja not_active Expired - Fee Related
  • 2002-04-19 CN CNB2005100804047A patent/CN100402499C/zh not_active Expired - Fee Related
  • 2002-04-19 AT AT05022069T patent/ATE538090T1/de active
  • 2002-04-19 WO PCT/JP2002/003952 patent/WO2002088094A1/ja active Application Filing
  • 2002-04-19 CN CNB2005100804032A patent/CN1321996C/zh not_active Expired - Fee Related
  • 2002-04-19 EP EP02720534A patent/EP1386912B1/en not_active Expired - Lifetime
  • 2002-04-19 CN CNB028085655A patent/CN1243735C/zh not_active Expired - Fee Related
  • 2002-04-19 EP EP02724628A patent/EP1391451B1/en not_active Expired - Lifetime
  • 2002-04-19 EP EP02720536A patent/EP1394152A4/en not_active Withdrawn
  • 2002-04-19 JP JP2002585394A patent/JP4251872B2/ja not_active Expired - Fee Related
  • 2002-04-19 WO PCT/JP2002/003950 patent/WO2002088092A1/ja active Application Filing
  • 2002-04-19 HU HU0400467A patent/HUP0400467A3/hu unknown
  • 2002-04-19 AT AT02724628T patent/ATE534627T1/de active
  • 2002-04-19 EP EP05022069A patent/EP1614680B1/en not_active Expired - Lifetime
  • 2002-04-19 EP EP02718622A patent/EP1391456B1/en not_active Expired - Lifetime
  • 2002-04-19 CZ CZ20032824A patent/CZ303865B6/cs not_active IP Right Cessation
  • 2002-04-19 CA CA2446924A patent/CA2446924C/en not_active Expired - Fee Related
  • 2002-04-19 MX MXPA03009497A patent/MXPA03009497A/es active IP Right Grant
  • 2002-04-19 AT AT02720534T patent/ATE425964T1/de not_active IP Right Cessation
  • 2002-04-19 IL IL15849102A patent/IL158491A0/xx unknown
  • 2002-04-19 US US10/475,045 patent/US20040242627A1/en not_active Abandoned
• 2003
  • 2003-10-16 NO NO20034632A patent/NO327849B1/no not_active IP Right Cessation
  • 2003-10-16 ZA ZA2003/08064A patent/ZA200308064B/en unknown
  • 2003-10-19 IL IL158491A patent/IL158491A/en not_active IP Right Cessation
• 2005
  • 2005-05-17 AU AU2005202135A patent/AU2005202135B2/en not_active Ceased
  • 2005-06-22 US US11/158,941 patent/US20050245592A1/en not_active Abandoned
• 2006
  • 2006-02-17 JP JP2006041255A patent/JP4464928B2/ja not_active Expired - Fee Related
  • 2006-02-17 JP JP2006041270A patent/JP4516922B2/ja not_active Expired - Fee Related
  • 2006-06-01 HK HK06106324A patent/HK1086269A1/xx not_active IP Right Cessation
• 2008
  • 2008-07-17 US US12/175,015 patent/US20090215795A1/en not_active Abandoned